“…[19][20][21] Therefore, Type I PDT can achieve a better antihypoxia outcome. Up to now, several kinds of PSs following the Type I pathway have been reported to achieve signicant advances, such as antennae-fullerene conjugates, 12 inorganic nanocomposites, 22,23 organometallic complexes 24,25 and metalorganic frameworks. 26,27 However, for these complicated materials, the severe immunotoxicity, poor reproducibility and complex pharmacokinetics hinder their clinical application to some degree.…”